Circulatory age-associated B cells: Their distinct transcriptomic characteristics and clinical significance in drug-naïve patients with rheumatoid arthritis
JG Kim, M Kim, BK Hong, YH Choe, JR Kim, N Lee… - Clinical …, 2024 - Elsevier
Age-associated B cells (ABCs) have been implicated in the pathogenesis of autoimmune
diseases. However, the global gene expression and clinical significance of circulatory ABCs …
diseases. However, the global gene expression and clinical significance of circulatory ABCs …
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial
N den Broeder, L Verhoef, YA de Man, MR Kok… - RMD open, 2024 - rmdopen.bmj.com
Background The REDO trial (REtreatment with Rituximab in RhEmatoid arthritis: Disease
Outcome after Dose Optimisation) showed similar disease activity for retreatment with …
Outcome after Dose Optimisation) showed similar disease activity for retreatment with …
Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience
Y Nie, N Zhang, J Li, D Wu, Y Yang, L Zhang… - Journal of Clinical …, 2024 - Springer
Objectives To investigate predictors of hypogammaglobulinemia (HGG) and severe infection
event (SIE) in patients with autoimmune disease (AID) receiving rituximab (RTX) therapy …
event (SIE) in patients with autoimmune disease (AID) receiving rituximab (RTX) therapy …
Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis
D Bertrand, A Deprez, M Doumen… - Musculoskeletal …, 2024 - Wiley Online Library
Objective The recommended dose of a rituximab course for the treatment of Rheumatoid
Arthritis (RA) consists of two infusions of 1000 mg with a 2‐week interval. Evidence is …
Arthritis (RA) consists of two infusions of 1000 mg with a 2‐week interval. Evidence is …
Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study
LD Veeken, MAA Opdam, LM Verhoef, C Popa… - …, 2024 - academic.oup.com
Objectives Rituximab (RTX) is a safe and effective treatment for RA. However, there are
some concerns about infection risk and preliminary data suggest dose and time …
some concerns about infection risk and preliminary data suggest dose and time …
Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
B Brando, A Gatti - Resistance to Anti-Cd20 Antibodies and Approaches …, 2024 - Elsevier
Immunosuppression has been centered on T cells, due to their role in allo-and
autoimmunity. Patients on rituximab for lymphomas improve their concomitant rheumatoid …
autoimmunity. Patients on rituximab for lymphomas improve their concomitant rheumatoid …
Uso de imunobiológicos no tratamento da Artrite Reumatoide
ITP Morais, JB Viana, LLF Almeida… - … Journal of Health …, 2023 - ojs.brazilianjournals.com.br
Este estudo objetivou caracterizar os principais fármacos imunobiológicos usados no
tratamento da Artrite Reumatoide (AR), para isso, pautou-se em estudos de caracterização …
tratamento da Artrite Reumatoide (AR), para isso, pautou-se em estudos de caracterização …
POS0176 DRUG RETENTION OF BIOLOGICS OR JAKI IN RHEUMATOID ARTHRITIS PATIENTS WHO FAILED TREATMENT WITH JAKI: RESULTS FROM THE …
N Yoshida, R Watanabe, W Yamamoto, K Murakami… - 2023 - ard.bmj.com
Background Few studies have addressed what is the optimal therapeutic option in patients
with rheumatoid arthritis (RA) who failed treatment with JAK inhibitors (JAKi). Objectives The …
with rheumatoid arthritis (RA) who failed treatment with JAK inhibitors (JAKi). Objectives The …
Low-dose rituximab for refractory idiopathic membranous nephropathy: A retrospective study
K Guo, X Xu, H Zhu, L Huang, H Li, X Li - 2023 - researchsquare.com
Background The efficacy of rituximab (RTX) in the treatment of idiopathic membranous
nephropathy (IMN) has been confirmed, but the specific dosing regimens have not been …
nephropathy (IMN) has been confirmed, but the specific dosing regimens have not been …
Sollten Patienten mit ANCA-assoziierten Vaskulitiden (AAV), die eine Erhaltungstherapie mit Rituximab erhalten, eine Cotrimprophylaxe bekommen?
H Mahrhofer - Zeitschrift für Rheumatologie, 2024 - Springer
Infektionserkrankungen stellen bei ANCA-assoziierten Vaskulitiden (AAV) vor allem imerstenErkrankungsjahrdieHaupttodesurs…
dar [1]. Die Prävalenz für schwere Infektionen unter einer Therapie mit Rituximab (RTX) bei …
dar [1]. Die Prävalenz für schwere Infektionen unter einer Therapie mit Rituximab (RTX) bei …